세계의 HIV 주사 시장 규모, 점유율, 동향 분석 : 유통 채널별, 지역별 전망과 예측(2023-2030년)

Global HIV Injection Market Size, Share & Trends Analysis Report By Distribution Channel (Hospital Pharmacy, Drugs Stores & Retail Pharmacies, and Others), By Regional Outlook and Forecast, 2023 - 2030

US $ 3,600 ￦ 5,197,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 4,320 ￦ 6,237,000

PDF (Multi User License)

PDF 보고서를 동일 기업의 10명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,048 ￦ 8,732,000

PDF (Corporate User License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계의 HIV 시장 규모는 2030년까지 28억 달러에 달하며, 예측 기간 중 CAGR 17.6%로 성장할 것으로 예측되고 있습니다.

또한 혁신적인 제형은 기존 경구용 약물에 비해 몇 가지 장점이 있으며, 시장에서의 채택과 수요 증가를 촉진하고 있습니다. 주사 요법은 일반적으로 경구용 약물보다 투여 빈도가 낮기 때문에 복잡한 투약 스케줄을 지키기 어려운 환자들에게 특히 유용합니다. 따라서 HIV/AIDS 치료를 위한 혁신적인 주사제 개발은 HIV 주사제 수요에 긍정적인 영향을 미치고 있습니다.

그러나 주사제를 포함한 HIV 치료의 높은 비용은 특히 저소득 및 중저소득 국가에서 HIV/AIDS를 앓고 있는 많은 사람들에게 여전히 치료 접근의 큰 장벽으로 작용하고 있으며, HIV 치료 비용에는 약물 자체의 가격뿐만 아니라 정기적인 모니터링, 정기적인 모니터링, 임상 검사, 의료진 방문 비용 등이 포함될 수 있으며, 이는 곧 환자에게 큰 경제적 부담이 될 수 있습니다. 따라서 높은 비용은 시장 확대에 걸림돌이 될 수 있습니다.

COVID-19 팬데믹은 시장에 큰 영향을 미쳤으며, 공급망의 다양한 측면과 환자의 치료 접근성에 영향을 미쳤습니다. 원자재 부족과 제조 지연으로 인해 전 세계 공급망에 혼란이 발생하여 주사제를 포함한 HIV 치료제에 영향을 미쳤습니다. 이러한 혼란은 일부 지역의 가용성에 영향을 미쳐 환자의 치료 중단으로 이어질 수 있습니다. 따라서 전염병은 시장에 부정적인 영향을 미쳤습니다.

목차

제1장 시장 범위와 조사 방법

• 시장의 정의
• 목적
• 시장 범위
• 세분화
• 조사 방법

제2장 시장 요약

• 주요 하이라이트

제3장 시장 개요

• 서론
  • 개요
    • 시장 구성과 시나리오
• 시장에 영향을 미치는 주요 요인
  • 시장 촉진요인
  • 시장 기회
  • 시장 억제요인
  • 시장이 해결해야 할 과제
• Porter's Five Forces 분석

제4장 세계의 HIV 주사 시장 : 유통 채널별

• 세계의 원내 약국 시장 : 지역별
• 세계의 드러그스토어·소매 약국 시장 : 지역별
• 세계의 기타 시장 : 지역별

제5장 세계의 HIV 주사 시장 : 지역별

• 북미
  • 북미의 HIV 주사 시장 : 국가별
    • 미국
    • 캐나다
    • 멕시코
    • 기타 북미
• 유럽
  • 유럽의 HIV 주사 시장 : 국가별
    • 독일
    • 영국
    • 프랑스
    • 러시아
    • 스페인
    • 이탈리아
    • 기타 유럽
• 아시아태평양
  • 아시아태평양의 HIV 주사 시장 : 국가별
    • 중국
    • 일본
    • 인도
    • 한국
    • 싱가포르
    • 말레이시아
    • 기타 아시아태평양
• 라틴아메리카·중동 및 아프리카
  • 라틴아메리카·중동 및 아프리카의 HIV 주사 시장 : 국가별
    • 브라질
    • 아르헨티나
    • 아랍에미리트
    • 사우디아라비아
    • 남아프리카공화국
    • 나이지리아
    • 기타 라틴아메리카·중동 및 아프리카

제6장 기업 개요

• GlaxoSmithKline PLC(GSK)
• Gilead Sciences, Inc
• ImmunityBio, Inc
• F Hoffmann-La Roche Ltd.
• Theratechnologies Inc
• Viriom, Inc
• AbbVie, Inc
• Brii Biosciences Limited
• Shionogi & Co, Ltd.
• Boehringer Ingelheim International GmbH

제7장 HIV 주사 시장의 성공 필수 조건

KSA

영문 목차

영문목차

The Global HIV Injection Market size is expected to reach $2.8 billion by 2030, rising at a market growth of 17.6% CAGR during the forecast period.

North America, particularly the United States, has a relatively high prevalence of HIV compared to other regions. Therefore, the North America segment captured $368.07 million revenue in the market in 2022. This high prevalence creates a substantial demand for HIV medications, including injectable therapies. North America is at the forefront of HIV research and treatment, leading to the development of new and innovative HIV medications, including injectable therapies.

The escalating prevalence of HIV/AIDS necessitates the development of more efficacious treatment modalities to alleviate symptoms and sustain life. This increased demand has driven pharmaceutical companies and researchers to develop new and innovative HIV injections to meet the growing needs of patients. Thus, the increasing prevalence of HIV is supporting the growth of the market.

Additionally, the innovative formulations offer several advantages over traditional oral medications, driving their adoption and increasing demand in the market. Injectable therapies typically require less frequent dosing than oral medications, which can be particularly beneficial for patients with difficulty adhering to complex medication schedules. Therefore, the development of innovative injectable formulations for the treatment of HIV/AIDS has had a positive impact on the demand for HIV injections.

However, the high cost of HIV treatment, including injectable medications, remains a significant barrier to access for many people living with HIV/AIDS, particularly in low- and middle-income countries. The cost of HIV treatment can include not only the price of the medication itself but also the cost of regular monitoring, laboratory tests, and healthcare provider visits, which can quickly add up to a substantial financial burden for patients. Hence, the high cost might hamper the expansion of the market.

The COVID-19 pandemic had a significant impact on the market, affecting various aspects of the supply chain and patient access to treatment. Raw material shortages and manufacturing delays followed disruptions in the global supply chain, which affected HIV medications, including injectable therapies. These disruptions impacted their availability in some regions, potentially leading to treatment interruptions for patients. Thus, the pandemic affected the market negatively

By Distribution Channel Analysis

Based on distribution channel, the market is divided into hospital pharmacy, drug stores & retail pharmacies, and others. The hospital pharmacy segment procured 46.2% revenue share in the market in 2022. Hospitals, clinics, and other healthcare facilities are major distribution points for HIV injections. They receive medications from pharmaceutical companies or wholesalers and distribute them to patients as part of their treatment regimens.

By Regional Analysis

Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The LAMEA segment witnessed 5.3% revenue share in the market in 2022. The LAMEA region has a relatively high prevalence of HIV, with certain countries in sub-Saharan Africa experiencing particularly high rates of infection. Governments in the LAMEA region have implemented various initiatives to address the HIV/AIDS epidemic, including funding for HIV/AIDS programs and improving access to treatment.

List of Key Companies Profiled

• GlaxoSmithKline PLC (GSK)
• Gilead Sciences, Inc.
• ImmunityBio, Inc.
• F. Hoffmann-La Roche Ltd.
• Theratechnologies Inc.
• Viriom, Inc.
• AbbVie, Inc.
• Brii Biosciences Limited
• Shionogi & Co., Ltd.
• Boehringer Ingelheim International GmbH

Global HIV Injection Market Report Segmentation

By Distribution Channel

• Hospital Pharmacy
• Drugs Stores & Retail Pharmacies
• Others

By Geography

• North America
  • US
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
• LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Table of Contents

Chapter 1.Market Scope & Methodology

• 1.1Market Definition
• 1.2Objectives
• 1.3Market Scope
• 1.4Segmentation
  • 1.4.1Global HIV Injection Market, by Distribution Channel
  • 1.4.2Global HIV Injection Market, by Geography
• 1.5Methodology for the research

Chapter 2.Market at a Glance

• 2.1Key Highlights

Chapter 3.Market Overview

• 3.1Introduction
  • 3.1.1Overview
    • 3.1.1.1Market Composition and Scenario
• 3.2Key Factors Impacting the Market
  • 3.2.1Market Drivers
  • 3.2.2Market Opportunities
  • 3.2.3Market Restraints
  • 3.2.4Market Challenges
• 3.3Porter's Five Forces Analysis

Chapter 4.Global HIV Injection Market by Distribution Channel

• 4.1Global Hospital Pharmacy Market by Region
• 4.2Global Drugs Stores & Retail Pharmacies Market by Region
• 4.3Global Others Market by Region

Chapter 5.Global HIV Injection Market by Region

• 5.1North America HIV Injection Market
  • 5.1.1North America HIV Injection Market by Distribution Channel
    • 5.1.1.1North America Hospital Pharmacy Market by Country
    • 5.1.1.2North America Drugs Stores & Retail Pharmacies Market by Country
    • 5.1.1.3North America Others Market by Country
  • 5.1.2North America HIV Injection Market by Country
    • 5.1.2.1US HIV Injection Market
      • 5.1.2.1.1US HIV Injection Market by Distribution Channel
    • 5.1.2.2Canada HIV Injection Market
      • 5.1.2.2.1Canada HIV Injection Market by Distribution Channel
    • 5.1.2.3Mexico HIV Injection Market
      • 5.1.2.3.1Mexico HIV Injection Market by Distribution Channel
    • 5.1.2.4Rest of North America HIV Injection Market
      • 5.1.2.4.1Rest of North America HIV Injection Market by Distribution Channel
• 5.2Europe HIV Injection Market
  • 5.2.1Europe HIV Injection Market by Distribution Channel
    • 5.2.1.1Europe Hospital Pharmacy Market by Country
    • 5.2.1.2Europe Drugs Stores & Retail Pharmacies Market by Country
    • 5.2.1.3Europe Others Market by Country
  • 5.2.2Europe HIV Injection Market by Country
    • 5.2.2.1Germany HIV Injection Market
      • 5.2.2.1.1Germany HIV Injection Market by Distribution Channel
    • 5.2.2.2UK HIV Injection Market
      • 5.2.2.2.1UK HIV Injection Market by Distribution Channel
    • 5.2.2.3France HIV Injection Market
      • 5.2.2.3.1France HIV Injection Market by Distribution Channel
    • 5.2.2.4Russia HIV Injection Market
      • 5.2.2.4.1Russia HIV Injection Market by Distribution Channel
    • 5.2.2.5Spain HIV Injection Market
      • 5.2.2.5.1Spain HIV Injection Market by Distribution Channel
    • 5.2.2.6Italy HIV Injection Market
      • 5.2.2.6.1Italy HIV Injection Market by Distribution Channel
    • 5.2.2.7Rest of Europe HIV Injection Market
      • 5.2.2.7.1Rest of Europe HIV Injection Market by Distribution Channel
• 5.3Asia Pacific HIV Injection Market
  • 5.3.1Asia Pacific HIV Injection Market by Distribution Channel
    • 5.3.1.1Asia Pacific Hospital Pharmacy Market by Country
    • 5.3.1.2Asia Pacific Drugs Stores & Retail Pharmacies Market by Country
    • 5.3.1.3Asia Pacific Others Market by Country
  • 5.3.2Asia Pacific HIV Injection Market by Country
    • 5.3.2.1China HIV Injection Market
      • 5.3.2.1.1China HIV Injection Market by Distribution Channel
    • 5.3.2.2Japan HIV Injection Market
      • 5.3.2.2.1Japan HIV Injection Market by Distribution Channel
    • 5.3.2.3India HIV Injection Market
      • 5.3.2.3.1India HIV Injection Market by Distribution Channel
    • 5.3.2.4South Korea HIV Injection Market
      • 5.3.2.4.1South Korea HIV Injection Market by Distribution Channel
    • 5.3.2.5Singapore HIV Injection Market
      • 5.3.2.5.1Singapore HIV Injection Market by Distribution Channel
    • 5.3.2.6Malaysia HIV Injection Market
      • 5.3.2.6.1Malaysia HIV Injection Market by Distribution Channel
    • 5.3.2.7Rest of Asia Pacific HIV Injection Market
      • 5.3.2.7.1Rest of Asia Pacific HIV Injection Market by Distribution Channel
• 5.4LAMEA HIV Injection Market
  • 5.4.1LAMEA HIV Injection Market by Distribution Channel
    • 5.4.1.1LAMEA Hospital Pharmacy Market by Country
    • 5.4.1.2LAMEA Drugs Stores & Retail Pharmacies Market by Country
    • 5.4.1.3LAMEA Others Market by Country
  • 5.4.2LAMEA HIV Injection Market by Country
    • 5.4.2.1Brazil HIV Injection Market
      • 5.4.2.1.1Brazil HIV Injection Market by Distribution Channel
    • 5.4.2.2Argentina HIV Injection Market
      • 5.4.2.2.1Argentina HIV Injection Market by Distribution Channel
    • 5.4.2.3UAE HIV Injection Market
      • 5.4.2.3.1UAE HIV Injection Market by Distribution Channel
    • 5.4.2.4Saudi Arabia HIV Injection Market
      • 5.4.2.4.1Saudi Arabia HIV Injection Market by Distribution Channel
    • 5.4.2.5South Africa HIV Injection Market
      • 5.4.2.5.1South Africa HIV Injection Market by Distribution Channel
    • 5.4.2.6Nigeria HIV Injection Market
      • 5.4.2.6.1Nigeria HIV Injection Market by Distribution Channel
    • 5.4.2.7Rest of LAMEA HIV Injection Market
      • 5.4.2.7.1Rest of LAMEA HIV Injection Market by Distribution Channel

Chapter 6.Company Profiles

• 6.1GlaxoSmithKline PLC (GSK)
  • 6.1.1Company Overview
  • 6.1.2Financial Analysis
  • 6.1.3Regional Analysis
  • 6.1.4Research & Development Expense
  • 6.1.5SWOT Analysis
• 6.1Gilead Sciences, Inc.
  • 6.1.1Company overview
  • 6.1.2Financial Analysis
  • 6.1.3Research & Development Expenses
  • 6.1.4SWOT Analysis
• 6.2ImmunityBio, Inc.
  • 6.2.1Company Overview
  • 6.2.2Financial Analysis
  • 6.2.3Regional Analysis
  • 6.2.4Research & Development Expenses
  • 6.2.5SWOT Analysis
• 6.3F. Hoffmann-La Roche Ltd.
  • 6.3.1Company Overview
  • 6.3.2Financial Analysis
  • 6.3.3Segmental and Regional Analysis
  • 6.3.4Research & Development Expense
  • 6.3.5SWOT Analysis
• 6.4Theratechnologies Inc.
  • 6.4.1Company Overview
  • 6.4.2Financial Analysis
  • 6.4.3Research & Development Expenses
  • 6.4.4SWOT Analysis
• 6.5Viriom, Inc.
  • 6.5.1Company Overview
  • 6.5.2SWOT Analysis
• 6.6AbbVie, Inc.
  • 6.6.1Company Overview
  • 6.6.2Financial Analysis
  • 6.6.3Regional Analysis
  • 6.6.4Research & Development Expense
  • 6.6.5SWOT Analysis
• 6.7Brii Biosciences Limited
  • 6.7.1Company Overview
  • 6.7.2Financial Analysis
  • 6.7.3Research & Development Expenses
  • 6.7.4SWOT Analysis
• 6.8Shionogi & Co., Ltd.
  • 6.8.1Company Overview
  • 6.8.2Financial Analysis
  • 6.8.3Research & Development Expenses
  • 6.8.4SWOT Analysis
• 6.9Boehringer Ingelheim International GmbH
  • 6.9.1Company Overview
  • 6.9.2Financial Analysis
  • 6.9.3Regional & Segmental Analysis
  • 6.9.4Research & Development Expenses
  • 6.9.5SWOT Analysis

Chapter 7.Winning Imperatives of HIV Injection Market

관련자료